). Hepatic fibrosis area was assessed by quantitative imaging of picrosirius red staining. Hepatic collagen content was assessed by hydroxyproline levels. Hepatic stellate cells (αSMA positive) and hepatic macrophages (CD68 positive) were identified by immunohistochemistry. Hepatic gene expression was determined by PCR and liver TGFβ1 content by ELISA.
RESULTS

CCl4 treated mice with deletion of the PAR-2 gene (PAR-2 -/-
) and the cytoplasmic domain of TF (TF §CT/ §CT ) developed significantly less hepatic fibrosis, characterised by reduced liver fibrosis area and hydroxyproline content, compared to control wildtype mice treated with CCl4. The observed reduction in histological fibrosis was accompanied by a significant decrease in the hepatic content of TGFβ, the prototypic fibrogenic cytokine, as well as fewer activated hepatic stellate cells and hepatic macrophages. Deletion of the TF cytoplasmic signalling domain reduced hepatic fibrosis to levels similar to those
INTRODUCTION
Chronic hepatocyte injury leads to a wound healing response that can result in excessive inflammation, collagen deposition and advanced hepatic fibrosis. The coagulation system is involved in the acute re sponse to injury with formation of a fibrin clot, but also plays an important role in the inflammatory signalling that perpetuates wound healing and tissue remodelling. The links between inflammation and coagulation occur through tissue factor (TF) and through protease activated receptors (PAR) although the relative contributions of each to inflammatory and fibrotic outcomes are unclear. TF is a transmembrane glycoprotein receptor with a pivotal role in hemostasis initiated by binding FⅦa, its principal ligand. Clot formation following TF ligation is well known, however downstream events also include expression of pro inflammatory cytokines such as interleukin (IL)6.
Evidence for this relationship is seen in healthy human subjects who demonstrate IL6 and IL8 induction following exposure to recombinant FVIIa and in mice expressing low TF levels (< 1% of wildtype) which show reduced inflammatory cytokine expression and mortality following lipopolysaccharide (LPS) exposure [1, 2] . The TF molecule has three domains; binding of the extracellular domain to Factor Ⅶ/Ⅶa initiates coagulation, the transmembrane domain has anchoring properties necessary for normal coagulation and the cytoplasmic domain, which is not required for coagu lant activity, plays a role in intracellular signalling. For example, binding of FⅦa to macrophage TF leads to phospholipase Cdependent intracellular calcium fluxes and reactive oxygen species production that requires an intact TF cytoplasmic domain [3] . In the liver, hepatocytes are the primary source of Factor Ⅶ/Ⅶ a. Constitutive hepatocyte expression of TF mRNA is low but can be upregulated in circulating monocytes by LPS [4] , monocyte chemotactic protein1 and platelet derived growth factor as well as by direct contact with platelets [4, 5] . The TF cytoplasmic domain also plays a regulatory role in PAR2 signalling. Mice with deletion of the cytoplasmic domain (TF §CT/ §CT ) demonstrate enhanced PAR2 dependent angiogenesis suggesting that the TF cytoplasmic domain acts as a negative regulator of PAR2 signalling [6] . Context may be important, however, as others have shown that the TF cytoplasmic domain is necessary for PAR-2 regulated inflammation [7] . A role for TFPAR2 signalling in the development of obesity and insulin resistance has recently been demonstrated. TFⅦaPAR2 signalling in adipocytes regulates weight gain and in macrophages promotes inflammation and insulin resistance [8] . Such pathways may play a role in the development of nonalcoholic fatty liver disease (NAFLD) as direct thrombin inhibition has been shown to reduce hepatic inflammation in murine NAFLD [9] . The aim of our study was to evaluate the role of the TF cytoplasmic domain in the hepatic inflammatory response and liver fibrogenesis following chronic injury. We have previously shown that PAR2 deficiency ameliorates experimental liver fibrosis [10] . Given the observed interactions between TF cytoplasmic domain and PAR-2 in angiogenesis and inflammation, we explored a possible relationship between the TF cytoplasmic domain and the PAR2 receptor in the development of liver fibrosis in mice with deletion of the TF cytoplasmic domain, deletion of PAR2 and deletion of both the TF cytoplasmic domain and PAR2.
MATERIALS AND METHODS
Animals
Mice on a 25%Swiss/25%129S/50% MF1 background with deletion of 18 of the 20 amino acids of the TF cytoplasmic domain (TF §CT/ §CT ) were generated by Crelox recombination as previously described and backcrossed 9 generations onto a C57BL6 background [11] . TF §CT/ §CT mice have normal development, coagulation and fertility. PAR2 knockout mice were generated as previously described [10] . Mice with deletion of both the TF cytoplasmic domain and PAR 2 (TF §CT/ §CT /PAR2 / ) were generated; these mice have normal develop ment, coagulation and fertility. Mice were allowed food and water ad libitum and were housed at a constant temperature in 12:12 hour lightdark cycle. Experimental protocols were approved by the Monash University Animal Ethics Committee and mice received humane care as specified under the Australian code of practice for the care and use of animals for scientific purposes.
Induction of hepatic fibrosis
Liver fibrosis was induced in male mice by twice weekly intraperitoneal injections of 1 μL/g body weight CCl4 mixed with olive oil (1:10) . Starting between 810 wk of age, four groups of mice were studied. TF §CT/ §CT (n = 9), TF §CT/ §CT /PAR2 / (n = 6) and wild type (WT) C57BL/6 (n = 10) all received CCl4 for 8 wk. A control group of WT C57BL/6 mice (n = 8) received olive oil alone for 8 wk as a vehicle control. 
Hepatic fibrosis assessment
Hepatic collagen content:
Hydroxyproline is an amino acid that stabilises collagen deposited in the liver and is exclusively associated with collagenous connective tissue and therefore is a good surrogate for quantification of collagen deposition [12] . Hepatic hydroxyproline content was quantified using liver tissue frozen in liquid nitrogen as previously described with minor modification [13] . Briefly, liver samples were weighed and hydrolysed in 2. 
Gene expression studies
Mouse RNA was extracted using the Qiagen RNeasy mini kit according to the manufacturer's instructions (Qiagen Pty Ltd, Hilden, Germany). Briefly, 0.02 to 0.03 g of liver was placed in RNAse free tube. 600 μL of RLT was added to each sample which was then vortexed for 15 min. The resultant lysate was pipetted into a QIA shredder spin column and centrifuged initially at full speed for 2 min, then the column was removed and the lysate was centrifuged for a further 3 min. The resultant supernatant was removed and added to equal volume of 50% ethanol, transferred to an RNeasy spin column, centrifuged for 15 s and the flow through discarded. Seven hundred microliter Buffer RW1 was added and the column was centrifuged for 15 s and followed by the addition of two aliquots of 500 μL of RPE, centrifuging in between for 15 s and 2 min respectively. The RNeasy spin column was placed in a new collection tube, centrifuged for 1 min and then 30 μL of RNasefree water was added directly to the spin column membrane, centrifuged and then a further 30 μL of RNasefree water was added. 
RESULTS
Hepatic fibrosis
Quantitative analysis of histological fibrosis by com puterassisted morphometry in CCl4treated WT mice showed a marked increase in liver fibrosis area (LFA) at 8 wk (3.39% ± 0.26%) compared to vehicle controls (LFA 0.7% ± 014%) (p < 0.0001). CCl4 administration induced similar levels of fibrosis in TF §CT/ §CT and TF §CT/ §CT / PAR2 / mice (1.76% ± 0.17% and 1.94% ± 0.11% respectively), which were similar to that seen with PAR2 / mice (LFA 2.09% ± 0.28%). Real time PCR analysis was performed (Power Sybr Green, Roche, Manheim, Germany) using a Rotor Gene 3000 light cycler (Qiagen Pty Ltd, Sydney, Australia) and the specific target mRNA of interest quantified as a ratio relative to 18S RNA content of the sample. 200 ng of cDNA was used per reaction. The primer sequences used in analysis are found in Table 1 .
Protein expression studies
Extracts were prepared from snap frozen liver by homogenisation in lysis buffer (TrisHCl 50 mmol/L, NaCl 150 mmol/L, EDTA 1 mmol/L, 1% Triton X100, 0.5% Tween20, 0.1% SDS) containing a protease inhibitor cocktail (#11836170, Roche Diagnostics, Mannheim, Germany) followed by centrifugation at 14000 × g for 15 min at 4 ℃. Supernatants were collected and activated with acetic acid/urea prior to analysis. TGFβ1 content of liver protein extracts were measured using a mouse TGFβ1 ELISA kit (R and D Systems Inc, Minneapolis, MN, United States). Plates were read using the BioRad microplate reader at 450 nm and TGFβ1 concentrations were calculated from the standard curve by the plate reader software.
Statistical analysis
Data are expressed as mean ± SEM. Statistical sig nificance was determined by oneway ANOVA with NewmanKeuls posttest for multiple comparisons or Student's ttest for comparisons between two groups as appropriate, using GraphPad Prism 5.03 for to WT mice (p < 0.0001 and p < 0.01 respectively), suggesting ECM remodelling is reduced in association with the lower levels of fibrosis seen at 8 wk in these mice.
Activated hepatic macrophages are decreased in TF §CT/ §CT and TF §CT/ §CT
/PAR-2 deficient mice
We used CD68 (macrosialin) to identify activated macro phages. Figure 6 ). We observed similar findings in PAR-2 / mice suggesting a role for PAR2 in macrophage recruitment and activation [9] . The current findings suggest that the TF cytoplasmic domain, as well as PAR2, may be involved in this process.
DISCUSSION
There is growing evidence in animal models and in humans that injuryrelated signalling through the pivotal coagulation receptors, TF and PAR, can drive hepatic fibrogenesis. A recent study of acute injury in mice given a single injection of CCl4 demonstrated elevated hepatocyte TF levels and tissue injury that were blocked by specific TF antisense oligonucleotide therapy [14] . In man, TF levels have been found to be over 100 fold higher in patients with cirrhosis compared to noncirrhotic patients [15] . PAR1 polymorphisms were shown to influence the hepatic fibrosis rate in Brazilian and European patients with chronic hepatitis C infection [16] . Resistance to activated protein C occurs in patients heterozygous for the factor V Leiden mutation leading to increased thrombin activity, which is a mitogen for hepatic stellate cells. Factor V Leiden heterozygosity has been associated with rapid fibrosis progression in hepatitis C patients [17] . Given our previous study showing that PAR2 deletion decreased hepatic fibrosis in mice and data showing that the TF cytoplasmic domain induces proinflammatory effects in macrophages we examined the relative contributions of TF and PAR2 in the development of toxininduced liver fibrosis.
We found that mice with deletion of the TF cyto plasmic domain had lower hepatic collagen content and less histological fibrosis than wild type mice following 8 wk of CCL4 exposure. This was accompanied by fewer αSMA positive cells histologically suggesting reduced hepatic stellate cell activation. There was significantly lower gene and protein expression of the key profibrogenic cytokine TGFβ and a reduction in MMP2 expression in TF §CT/ §CT mice. These data suggest that activation of the cytoplasmic domain of TF promotes hepatic fibrosis by inducing a profibrogenic phenotype in hepatic stellate cells. In angiogenesis, the cytoplasmic domain of TF acts as a negative regulator of PAR2. If that were true in this model of liver fibrosis, then loss of the cytoplasmic domain and thus loss of negative regulation of PAR2, should lead to increased fibrosis through increased PAR2 activation. However this was not observed in our study. In fact, the protection from experimentally induced liver fibrosis that the TF §CT/ §CT mice were afforded was similar to that which we previously observed in mice with PAR 2 deficiency [10] . This observation is consistent with the observation in other studies that TF may be necessary for PAR-2 mediated inflammation [7] . Factor Ⅶa induced calcium fluxes in macrophages in vitro. In vivo studies in which TF/Factor Ⅶa interactions were blocked using a TF antibody led to reduced expression of MHC class Ⅱ and β2 integrin leucocyte adhesion molecules which are markers of macrophage activation [3] . There is increasing interest in macrophage pheno types in liver disease as classically activated M1 macrophages are proinflammatory and alternatively activated M2 macrophages are antiinflammatory. A recent study has shown that TF §CT/ §CT mice fed a high fat diet demonstrated reduced inflammatory macrophages in adipose tissue with reduced proinflammatory cytokine production, suggesting that TF signalling is directly involved in regulating macrophage inflammation and may sustain M1 polarisation. Interestingly, there was no additive effect of double deletion of TF and PAR2 on diet induced obesity, similar to the outcomes we have observed in hepatic fibrosis [8] . In conclusion we have established, for the first time to our knowledge, that deletion of the TF cytoplasmic domain significantly reduces experimental hepatic fibrosis. Furthermore we have shown that deletion of the cytoplasmic domain in addition to PAR2 de ficiency does not lead to more profound protection from fibrosis and in fact that mice lacking the tissue factor cytoplasmic domain phenocopy PAR-2 deficiency. This demonstrates that the tissue factor cytoplasmic domain is involved in pathological TFPAR2 signalling. The potential to intervene in this process by inhibiting thrombin or FXa is relevant given the widespread clinical availability of direct inhibitors. For example, administration of argatroban, a direct thrombin inhibitor, to mice fed a Western diet significantly reduced hepatic macrophage accumulation, profibrogenic gene expression and hepatic steatosis suggesting that thrombin inhibition could reduce the risk of fibrosis development in NAFLD patients [9] . It would be prudent to limit therapeutic coagulation inhibition to non cirrhotic patients at risk of fibrosis progression in order to avoid the risk of bleeding events in cirrhotic patients. This makes the cytoplasmic domain of TF an attractive therapeutic target, as its deletion would not impact on coagulation and thus could be a potentially beneficial antifibrotic strategy in patients with advanced liver disease.
COMMENTS
Background
Globally, liver cirrhosis is the sixth most common cause of life-years lost to premature mortality. Cirrhosis represents a "wound healing" response to persistent inflammatory injury (commonly due to fat, alcohol or hepatitis viruses) that can lead to excessive collagen deposition and disruption of normal liver architecture. The coagulation system is active in both the acute response to organ injury as well as in inflammatory signaling that perpetuates the wound healing response. The molecular link between inflammation and coagulation occurs through tissue factor (TF) and protease activated receptors (PARs) although the relative contribution of each remains unclear.
Research frontiers
Currently no anti-fibrotic agents are available for patients with cirrhosis. Liver transplantation may be the only effective treatment for those who progress to hepatic decompensation or develop hepatocellular carcinoma. In order to develop therapeutic anti-fibrotic agents, the authors must understand the cellular and molecular pathways that cause inflammation and fibrosis.
Innovations and breakthroughs
The authors previously showed that PAR-2 was involved in hepatic fibrosis, since deletion of the pAR-2 gene resulted in decreased fibrosis in mice. Since the TF cytoplasmic domain is a negative regulator of PAR-2 in angiogenesis, they explored this relationship in a model of liver fibrosis. They found that mice with low levels of the cytoplasmic domain of TF had less fibrosis than control mice with fewer activated hepatic stellate cells, the principal liver cells that COMMENTS produce collagen, and fewer activated macrophages, which express cytokines that drive HSC activation.
Applications
Inhibition of coagulation, for example, by direct thrombin inhibitors, could prevent fibrosis progression in cirrhotic patients but would increase the risk of bleeding events in a patient group at high risk for such events. However, direct targeting of the cytoplasmic domain of TF, which is involved in intracellular signalling but not in coagulation, could be a potentially beneficial anti-fibrotic strategy in cirrhotic patients.
Peer-review
The paper by Knight et al describes that genetic ablation of the intracellular portion of TF or of PAR2 downstream to TF both reduce in a non-additive fashion fibrosis in the liver induced by treating mice with CCL4. Some insights in the mechanism of action of the two manipulations were provided by histological data indicating that they both reduce the frequency of activated smooth muscle cells and activated macrophages and the levels of TGF-β, a known profibrotic factor, in the liver. The results are interesting in view of the fact that liver fibrosis is an unmet clinical need which involves a large number of patients and that drugs targeting TF have been developed and are currently in clinical trials for treatment of thrombosis.
